stuartlpbi | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

About: Stuart Cantor

Website: http://stuartlpbi.wordpress.com
Details: I have a Ph.D. in pharmaceutical sciences and my expertise is in solid oral dosage formulation development and controlled-release technologies. I also have a deep background in intellectual property in the areas of chemistry, pharma, medical device, and biotech.

Posts by Stuart Cantor:

February 8, 2016 Bio-MEMS Technologies: Devices, Tissue Engineering & Drug Delivery, Presentation by Stuart Cantor, Ph.D. on 2/4/16

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,027 other followers
Recent Posts
- COVID concern in Cardiology: Asymptomatic patients who have been previously infected demonstrating evidence on MRI of scarring or myocarditis September 21, 2020
- The Role of Cholesterol Crystals in increase of NLRP3 Inflammasome affecting Coronary Artery Disease & Carotid Atherosclerosis September 15, 2020
- Coronavirus damages the Human Heart Muscle: Disrupting Sarcomeres and Displacing DNA September 14, 2020
- Multiple Major Scientific Journals Will Fully Adopt Open Access Under Plan S September 10, 2020
- Bradykinin Hypothesis: Potential Explanation for COVID-19 September 8, 2020
- Project Patient Voice September 7, 2020
- Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition September 4, 2020
- Why Blood Clots Are a Major Problem in Severe COVID-19 September 1, 2020
- Sex Differences in Immune Responses that underlie COVID-19 Disease Outcomes September 1, 2020
- Thymic Dysfunction and Atrophy in COVID-19 Disease Complicated by Inflammation, Malnutrition and Cachexia September 1, 2020
Archives
Archives
Categories
Categories
Meta